As of Feb. 9, 2013, Guru Seth Klarman
, legendary value investor of The Baupost Group, added 49.69% to his Idenix Pharmaceuticals Inc. (IDIX
) mega position currently at 24,740,200 shares. The current share price is $3.54 with a change from average down 28%. Klarman first bought a new IDIX holding of 1,255,700 shares, in the quarter ending June 30, 2011.
With operations in the U.S. and Europe, Idenix Pharmaceuticals develops drugs for the treatment of human viral diseases, focusing on the treatment of hepatitis B and hepatitis C, called HCV, the cause of liver disease. The company’s product pipeline shows it is currently developing “inhibitors” to inhibit HCV replication and to treat HIV/AIDS. Continue Reading »